Dr. Robert S. Wirthlin, M.D.
Ophthalmology (Ophthalmology Physician)
427 S Bernard St
Spokane, WA 99204
Who else practices at this address →
Spokane County includes primary care (67% of residents) and dental (43% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 757
Licensed in Washington since 2006, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
WA license MD00046133 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Deaconess Medical Center Spokane, WA
Medical groups
- Spokane Eye Clinic Ps (36 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 757
- Services billed
- 69,239
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 43,920 | 119 |
| Imaging of retina | 2,683 | 732 |
| Injection, aflibercept, 1 mg | 2,434 | 213 |
| Injection of drug into eye | 2,017 | 348 |
| Injection, ranibizumab, 0.1 mg | 929 | 35 |
| Established patient complete exam of visual system | 469 | 414 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 300 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 278 | 195 |
| Established patient office or other outpatient visit, 30-39 minutes | 158 | 144 |
| Compounded drug, not otherwise classified | 141 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Spokane, WA | 153 |
| Ofloxacin Other prescribers in Spokane, WA | 102 |
| Atropine Sulfate | 98 |
| Timolol Maleate Other prescribers in Spokane, WA | 44 |
| Difluprednate | 42 |
| Ketorolac Tromethamine Other prescribers in Spokane, WA | 35 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Spokane, WA | 21 |
| Brimonidine Tartrate Other prescribers in Spokane, WA | 18 |
| Ilevro (nepafenac) | 16 |
| Fluorometholone Other prescribers in Spokane, WA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 37 payments worth $33,634 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $33,065 |
|---|---|
| Astellas Pharma US Inc | $267 |
| AbbVie Inc. | $198 |
| Genentech USA, Inc. | $70.14 |
| Neurotech Pharmaceuticals, Inc. | $18.01 |
| Regeneron Pharmaceuticals, Inc. | $17.04 |
| Compensation for services other than consulting (speaking, faculty) | $29,239 |
|---|---|
| Travel and Lodging | $3,360 |
| Food and Beverage | $1,036 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $7,520 |
| Regeneron Healthcare Solutions, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $7,520 |
| Regeneron Healthcare Solutions, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $4,700 |
| Regeneron Healthcare Solutions, Inc. Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $4,230 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $3,749 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,520 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SEATTLE, WA · in-kind | $732 |
| Regeneron Healthcare Solutions, Inc. Oct 1, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLEVUE, WA · in-kind | $546 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to AUBURN, WA · in-kind | $515 |
| Regeneron Healthcare Solutions, Inc. Feb 20, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SEATTLE, WA · in-kind | $432 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLINGHAM, WA · in-kind | $20.00 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $3,749 |
| Regeneron Healthcare Solutions, Inc. Oct 1, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLEVUE, WA · in-kind | $546 |
| Regeneron Healthcare Solutions, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $7,520 |
| Regeneron Healthcare Solutions, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $4,700 |
| Regeneron Healthcare Solutions, Inc. Sep 27, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLEVUE, WA · in-kind | $195 |
| Regeneron Healthcare Solutions, Inc. Sep 27, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLEVUE, WA · in-kind | $157 |
| Regeneron Healthcare Solutions, Inc. Aug 29, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BELLEVUE, WA · in-kind | $399 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,520 |
| Regeneron Healthcare Solutions, Inc. Apr 8, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to AUBURN, WA · in-kind | $34.00 |
| Regeneron Healthcare Solutions, Inc. Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $4,230 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $7,520 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SEATTLE, WA · in-kind | $732 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to AUBURN, WA · in-kind | $515 |
| Regeneron Healthcare Solutions, Inc. Mar 1, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SEATTLE, WA · in-kind | $330 |
| Regeneron Healthcare Solutions, Inc. Feb 20, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SEATTLE, WA · in-kind | $432 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $376,200 in research payments for these studies, mostly to the institutions running them.
- MAD to assess the safety tolerability and PK PD in nAMD patients
Genentech, Inc. - A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - IAMD Observational Study
Genentech, Inc. - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Real world long term data collection for roche ophthalmology products voyager
F. Hoffmann-la Roche AG - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.